Jerusalem-based Oramed expects the study at Hadassah University to conclude by the end of 2008.
Oral drug delivery system developer Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) reported an early step in an oral version of a diabetes treatment.
The firm has launched pre-clinical trials of ORMD 0901, a GLP (glucagon-like peptide)1-analog. ORMD 0901 belongs to the Incretin family of drugs which helps to manage diabetes, including reduction in blood glucose levels and inhibiting glucagon secretion.
Incretins have been cited in causing regeneration of pancreatic insulin secreting cells, and in tissue protective properties including protection of the heart. GLP1 and analogs are associated with gradual weight loss, which is beneficial to diabetes patients.
Jerusalem-based Oramed plans to conduct ORMD 0901 trials at Hadassah University Medical Center, and they are expected to conclude by the end of 2008.
Published by Globes [online], Israel business news - www.globes-online.com - on September 17, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008